A randomized, double-blind, phase II trial of paclitaxel + carboplatin + bevacizumab with or without apomab in patients with previously untreated, advanced-stage non-small cell lung cancer

Trial Profile

A randomized, double-blind, phase II trial of paclitaxel + carboplatin + bevacizumab with or without apomab in patients with previously untreated, advanced-stage non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Drozitumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 15 Feb 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 15 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top